Drug intelligence / Profile preview

Rukeshu

Development stage: Unknown
Lead developer: Shaanxi Licai Group Xianyang Licai Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Rukeshu is a botanical drug candidate, likely a Traditional Chinese Medicine (TCM) formulation, developed by Shaanxi Licai Group Xianyang Licai Pharmaceutical Co., Ltd. for the treatment of breast hyperplasia. It is formulated as an oral capsule. The drug was evaluated in a Phase II, randomized, double-blind, parallel-group clinical trial (CTR20130114) to assess its efficacy and safety at various doses compared to placebo in female patients. The treatment aims to alleviate symptoms such as breast pain and glandular nodules, which are characteristic of breast hyperplasia.

Brand names: Rukeshu
Other names: Rukeshu Capsule乳渴舒胶囊

Beyond the preview

Go deeper on Rukeshu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rukeshu.

Explore the full profile